Cometriq (cabozantinib) — United Healthcare

Preferred products

• Lenvima (lenvatinib)
• Nexavar (sorafenib)

Initial criteria

• One of the following: Diagnosis of medullary carcinoma OR All of the following: Diagnosis of one of the following: Follicular carcinoma; Oncocytic cell carcinoma; Papillary carcinoma AND Disease is progressive after treatment with one of the following: Lenvima (lenvatinib); Nexavar (sorafenib) AND Disease is at least one of the following: Symptomatic iodine-refractory; Unresectable locoregional recurrent or persistent disease; Distant metastatic disease

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Cometriq therapy

Approval duration

12 months